[Systemic and surgical management of metastatic renal cell carcinoma].
Several targeted therapies have become available for first-line (sunitinib, bevacizumab, pazopanib, temsirolimus) and second-line (sorafenib, pazopanib, everolimus) use in recent years. The superior outcomes achieved with these targeted agents have led to replacement of the formerly administered cytokines. New developments have raised the question of whether patients benefit from sequential therapies with tyrosine kinase inhibitors and/or whether combination regimes can improve clinical outcomes. This review gives an overview of the current therapeutic options for first- and second-line treatment in metastatic RCC as well as sequential and combination therapies. Adjuvant and neoadjuvant treatment options are being discussed. Furthermore, this review addresses surgical alternatives in the treatment of RCC.
Klinik für Urologie und Urologische Onkologie, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 30625 Hannover, Deutschland.
M W
MW
Kramer
A S
AS
Merseburger
I
I
Peters
S
S
Waalkes
M A
MA
Kuczyk
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D003131:Combined Modality Therapy; D016207:Cytokines / Q000627:therapeutic use; D019983:Guideline Adherence; D006801:Humans; D007680:Kidney Neoplasms / Q000401:mortality / Q000628:therapy*; D020360:Neoadjuvant Therapy; D009392:Nephrectomy; D016032:Randomized Controlled Trials as Topic
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D016207:Cytokines